- Home
- AEYE vs NTHI Comparison
AEYE vs NTHI Comparison
Compare AEYE & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- NTHI
- Stock Information
- Founded
- AEYE 2005
- NTHI 2008
- Country
- AEYE United States
- NTHI United States
- Employees
- AEYE N/A
- NTHI N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- AEYE Technology
- NTHI Health Care
- Exchange
- AEYE Nasdaq
- NTHI Nasdaq
- Market Cap
- AEYE 138.0M
- NTHI 142.5M
- IPO Year
- AEYE N/A
- NTHI N/A
- Fundamental
- Price
- AEYE $11.81
- NTHI $4.26
- Analyst Decision
- AEYE Strong Buy
- NTHI
- Analyst Count
- AEYE 5
- NTHI 0
- Target Price
- AEYE $26.40
- NTHI N/A
- AVG Volume (30 Days)
- AEYE 67.4K
- NTHI 23.3K
- Earning Date
- AEYE 07-24-2025
- NTHI 01-01-0001
- Dividend Yield
- AEYE N/A
- NTHI N/A
- EPS Growth
- AEYE N/A
- NTHI N/A
- EPS
- AEYE N/A
- NTHI N/A
- Revenue
- AEYE $36,851,000.00
- NTHI $79,990.00
- Revenue This Year
- AEYE $20.16
- NTHI N/A
- Revenue Next Year
- AEYE $18.74
- NTHI N/A
- P/E Ratio
- AEYE N/A
- NTHI N/A
- Revenue Growth
- AEYE 16.52
- NTHI 13.52
- 52 Week Low
- AEYE $8.91
- NTHI $4.11
- 52 Week High
- AEYE $34.85
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- AEYE 46.36
- NTHI N/A
- Support Level
- AEYE $11.27
- NTHI N/A
- Resistance Level
- AEYE $12.17
- NTHI N/A
- Average True Range (ATR)
- AEYE 0.57
- NTHI 0.00
- MACD
- AEYE -0.08
- NTHI 0.00
- Stochastic Oscillator
- AEYE 32.14
- NTHI 0.00
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").